Back to results
US 2026/0062705 A1Published application
Treatment for ovarian cancer with oligonucleotides targeting fibroblast activation protein alpha
OwnerShuang HUANG, Bin LIinventors
Life of this patent
Estimating the term…
Abstract
Fibroblast activation protein a (FAP) is a tumor-specific protein and well characterized for its function in tumorigenicity. However, agents against its enzymatic activity or monoclonal antibodies against its cell surface presence are unsuccessful in clinic for uncharacterized reason. In this disclosure, provided is an anti-FAP siRNA and FAP-silencing oligonucleotides comprising anti-FAP siRNAs linked at both ends to aptamers recognizing cancer markers, in particular aptamers recognizing epithelial cell adhesion molecule (EpCAM).
Claims14
A FAP silencing oligonucleotide comprising an anti-FAP siRNA comprising
- (1) a sense oligonucleotide of SEQ ID NO:3 or a biologically active fragment or variant thereof, and
- (2) an antisense oligonucleotide of SEQ ID NO:4 or a biologically active fragment or variant thereof,
- wherein the sense oligonucleotide and antisense oligonucleotide comprise 2′-fluoro-deoxyguanosine or natural deoxyguanosine.
Dependencies are inferred from the claim text.